Pharmaceuticals face 100% tariffs in US US considers 100% tariffs on pharmaceuticals, impacting drug prices. Scope and exemptions unclear, s...

US considers 100% tariffs on pharmaceuticals, impacting drug prices. Scope and exemptions unclear, says Brookings Institution's Richard Frank. #Pharmaceuticals #News

EPA moves to designate microplastics and pharmaceuticals as contaminants in drinking water The Environmental Protection Agency proposed Thursday to include microplastics and pharmaceuticals on a list of contaminants in drinking water for the first time, a step that could lead to new

EPA moves to designate #microplastics and #pharmaceuticals as #contaminants in #drinkingwater not currently regulated under the Safe Drinking Water Act www.thecanadianpressnews.ca/world/epa-mo...

#joke #funny #humor #comedy #meme #memes #shitposting #COVID #WHO #CDC #PHARMACEUTICALS #CONSPIRACY #KAREN

Hellmann expands healthcare logistics with new Dubai South hub Located in Dubai South’s Logistics District, the site has access to Jebel Ali Port via a bonded corridor and cargo terminals at Al Maktoum Airport.

Located in Dubai South’s Logistics District, the site has access to Jebel Ali Port via a bonded corridor and cargo terminals at #AlMaktoumAirport.

#HellmannWorldwideLogistics #DubaiSouth #JebelAliPort #healthcare #healthcarelogistics #pharma #MiddleEast #pharmaceuticals #medicalproducts

JPMorgan Reduces Stake in Indivior While Other Funds Increase Investments JPMorgan Chase & Co. reduced its holdings in Indivior PLC by 47% during the third quarter, selling 183,798 shares and retaining 207,588 shares valued at approximately $5.01 million, representing about 0.15% of the company. Meanwhile, other institutional investors significantly increased their stakes. Oaktree Capital Management LP added over 246 million shares, raising its total holdings to roughly $6.22 billion, while Divisadero Street Capital Management LP increased its position to over 3.36 million shares valued at $81 million. Goldentree Asset Management LP and Jacobs Levy Equity Management Inc. acquired new stakes valued at $42.63 million and $33.5 million, respectively. Insider activity included purchases by directors Keith Humphreys and Daniel A. Ninivaggi, boosting their ownership by 15.42% and 4.80%, respectively. Analysts have varied perspectives: HC Wainwright increased its price target to $48 with a 'buy' rating, Zacks Research upgraded Indivior to 'strong-buy,' and Weiss Ratings lowered its rating to 'hold.' Indivior, a specialty pharmaceutical company focusing on addiction and mental health treatments, recently reported strong earnings, beating estimates with $0.82 EPS on $358 million revenue. Institutional investors own 60.33% of the stock, which trades at a market cap of $3.71 billion, with a twelve-month high of $38.00 and a low of $8.64.

JPMorgan Reduces Stake in Indivior While Other Funds Increase Investments

🤖 IA: It's not clickbait ✅
👥 Usuarios: It's not clickbait ✅

#investments #stocks #pharmaceuticals

View full AI summary:

PlaneAlert ICAO: A70E5B Tail: N554AV Flt: N554AV
Owner: AbbVie
Aircraft: Gulfstream G600
2026-04-03 10:46:50 CEST
GA6C Bizjet Biotech Pharmaceuticals
adsb planefence planealert by kx1t - wiki - adsbexchange - planefence

Pharmaceuticals face 100% tariffs in US US considers 100% tariffs on pharmaceuticals. Impact unclear due to potential exemptions and deals, ...

US considers 100% tariffs on pharmaceuticals. Impact unclear due to potential exemptions and deals, says Brookings Institution's Richard Frank. #pharmaceuticals #News

EPA Proposes New Drinking Water Rules Targeting Microplastics and Pharmaceuticals Across the U.S., Raising Concerns About What’s in Your Tap Water!
👉 Read the full story at NewsLink7.com

#Microplastics #DrinkingWater #EPA #WaterSafety #Pharmaceuticals #News #WorldNews #Noticias

US imposes 100 per cent tariff on patented drugs - Yes Punjab News US to impose up to 100% tariffs on patented drug imports, citing national security and supply chain risks under Trump policy.

US imposes 100 per cent tariff on patented drugs yespunjab.com?p=235771

#USTariffs #Pharmaceuticals #DonaldTrump #TradePolicy #USNews #BigPharma #DrugPrices #SupplyChain #APIs #GlobalTrade #IndiaPharma #ChinaPharma #HealthcarePolicy #EconomicNews

Trump signs order threatening up to 100% tariffs on pharmaceuticals Donald Trump unveiled sweeping new pharmaceutical tariffs on Thursday that could reach 100% unless drugmakers strike pricing deals with his administration. The move, tied to national security concerns...

#Evil #Trump #UnitedStates
#Pharmaceuticals #Tariffs

www.france24.com/en/americas/...

Bright Path Supports New Tariffs on Imported Pharmaceuticals amid National Security Concerns Bright Path welcomes President Trump's new tariffs on imported pharmaceuticals, advocating for American manufacturing and national security. The company is already operating domestically to produce essential medicines.

Bright Path Supports New Tariffs on Imported Pharmaceuticals amid National Security Concerns #United_States #Mesa #pharmaceuticals #Tariffs #Bright_Path

Original post on masto.ai

#MafiaState

I’m all for lower drug prices, but this will hurt #patients most.

#Trump sets 100% #drug #tariffs on companies that haven’t lowered prices
Makers of patented #pharmaceuticals can escape the import tax by agreeing to join Trump’s “most favored nation” program to reduce US drug […]

Innocan Pharma FY Results Show C$12.3m Net Loss Innocan reported FY2025 revenue of C$2.1m and a net loss of C$12.3m on Apr 2, 2026; cash C$6.8m implies roughly six months runway at estimated burn.

Innocan Pharma FY Results Show C$12.3m Net Loss: Innocan reported FY2025 revenue of C$2.1m and a net loss of C$12.3m on Apr 2, 2026; cash C$6.8m implies roughly six months runway at estimated burn. 👈 Read full analysis #InnocanPharma #Pharmaceuticals #FinancialResults #NetLoss #RevenueReport

PureTech Publishes Phase 2b IPF Results PureTech published Phase 2b IPF results on Apr 2, 2026 (Investing.com). IPF median survival ~3–5 years; two drugs have been approved since 2014, shaping commercial hurdles.

PureTech Publishes Phase 2b IPF Results: PureTech published Phase 2b IPF results on Apr 2, 2026 (Investing.com). IPF median survival ~3–5 years; two drugs have been approved since 2014, shaping commercial hurdles. 👈 Read full analysis #PureTech #IPF #Phase2b #ClinicalTrials #Pharmaceuticals

#Pharmaceuticals and personal care products and their sublethal and lethal effects in #aquatic organisms

cdnsciencepub.com/doi/full/10....

#personalcareproducts
#PPCPs
#prescriptiondrugs
#fragrances
#cosmetics
#contaminants
#sewage
#wastewater
#persistence
#bioaccumulation
#toxicity

Skye Bioscience Doses First Patient in Nimacimab Study Skye dosed the first patient in the nimacimab expansion study on Apr 2, 2026, marking an operational milestone; enrollment pace and biomarker data will determine impact.

Skye Bioscience Doses First Patient in Nimacimab Study: Skye dosed the first patient in the nimacimab expansion study on Apr 2, 2026, marking an operational milestone; enrollment pace and biomarker data… 👈 Read full analysis #SkyeBioscience #Nimacimab #ClinicalTrials #Biotechnology #Pharmaceuticals

Lupin Completes Acquisition of VISUfarma to Expand Ophthalmology Portfolio Lupin Limited has successfully finalized its acquisition of VISUfarma, enhancing its specialized ophthalmology offerings and boosting its European market presence.

Lupin Completes Acquisition of VISUfarma to Expand Ophthalmology Portfolio #India #Mumbai #pharmaceuticals #Lupin_Limited #VISUfarma

The U.S. government is preparing to impose new tariffs on pharmaceutical imports, according to a report from the Financial Times. #US #Tariffs #Pharmaceuticals

PlaneAlert ICAO: A70E5B Tail: N554AV
Owner: AbbVie
Aircraft: Gulfstream G600
2026-04-01 18:03:26 CEST
GA6C Bizjet Biotech Pharmaceuticals
adsb planefence planealert by kx1t - wiki - adsbexchange - planefence

BioXcel Therapeutics: FDA Accepts IGALMI Application FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts.

BioXcel Therapeutics: FDA Accepts IGALMI Application: FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts. 👈 Read full analysis #BioXcelTherapeutics #IGALMI #FDANews #Pharmaceuticals #DrugApproval

#Wednesday #WednesdayVibes #HumpDay #4040rec #medicalsalesjobs #BusinessDevelopment #commercial #territorymanagement #marketaccess #marketing #leadership #peoplemanagement #pharmaceuticals #firstlinemanagement #internalsales #telesales #accountmanagement #healthcare #medtech #biotech #healthtech

#MEME #MEMES #FUNNY #HUMOR #JOKE #COMEDY #SHITPOSTING #pharmaceuticals #Mentalhealth #autism

HCW Biologics Q4 Results Signal Pipeline Focus HCW Biologics reported Q4 results on Mar 31, 2026 (21:40:34 GMT); company emphasized pipeline sequencing and management signaled near-term clinical milestones rather than headline revenue metrics.

HCW Biologics Q4 Results Signal Pipeline Focus: HCW Biologics reported Q4 results on Mar 31, 2026 (21:40:34 GMT); company emphasized pipeline sequencing and management signaled near-term clinical milestones… 👈 Read full analysis #HCWBiologics #Biotech #Pharmaceuticals #ClinicalTrials #Q4Results

Royalty Pharma Hits 52-Week High at $47.87 Royalty Pharma (RPRX) reached a 52-week high of $47.87 on Mar 31, 2026 (Investing.com); the move raises valuation and cash-flow durability questions for royalty-backed pharma financing.

Royalty Pharma Hits 52-Week High at $47.87: Royalty Pharma (RPRX) reached a 52-week high of $47.87 on Mar 31, 2026 (Investing.com); the move raises valuation and cash-flow durability questions for royalty-backed pharma… 👈 Read full analysis #RoyaltyPharma #Biotech #Pharmaceuticals #Investing #Stocks

Samsung Biologics Completes GSK MD Facility Deal Samsung Biologics closed the acquisition of GSK's Maryland biologics facility on Mar 31, 2026, expanding its U.S. footprint and changing CDMO competitive dynamics.

Samsung Biologics Completes GSK MD Facility Deal: Samsung Biologics closed the acquisition of GSK's Maryland biologics facility on Mar 31, 2026, expanding its U.S. footprint and changing CDMO competitive dynamics. 👈 Read full analysis #SamsungBiologics #GSK #Biologics #CDMO #Pharmaceuticals

Centessa Pharmaceuticals Hits Record $40.03 on Mar 31 Centessa (CNTA) reached an all-time high of $40.03 on Mar 31, 2026 (Investing.com), prompting reassessment of its multi-program valuation and catalyst calendar.

Centessa Pharmaceuticals Hits Record $40.03 on Mar 31: Centessa (CNTA) reached an all-time high of $40.03 on Mar 31, 2026 (Investing.com), prompting reassessment of its multi-program valuation and catalyst… 👈 Read full analysis #CentessaPharmaceuticals #Biotech #Investing #Pharmaceuticals #Stocks

Telomir Pharmaceuticals Files IND for Telomir-1 in TNBC Telomir filed an IND on Mar 31, 2026 for Telomir-1 in TNBC; FDA has 30 days to review, with potential Phase I start in H2 2026 and TNBC constituting ~10–15% of cases.

Telomir Pharmaceuticals Files IND for Telomir-1 in TNBC: Telomir filed an IND on Mar 31, 2026 for Telomir-1 in TNBC; FDA has 30 days to review, with potential Phase I start in H2 2026 and TNBC… 👈 Read full analysis #TelomirPharmaceuticals #ClinicalTrials #TNBC #BreastCancer #Pharmaceuticals

SCYNEXIS Acquires SCY-770 for Kidney Disease SCYNEXIS announced on Mar 31, 2026 the acquisition of SCY-770 for a rare kidney disease; regulatory incentives apply for populations under 200,000 in the U.S.

SCYNEXIS Acquires SCY-770 for Kidney Disease: SCYNEXIS announced on Mar 31, 2026 the acquisition of SCY-770 for a rare kidney disease; regulatory incentives apply for populations under 200,000 in the U.S. 👈 Read full analysis #SCYNEXIS #KidneyDisease #RareDisease #OrphanDrug #Pharmaceuticals

Lantern Pharma Flags $15B–$20B Market Opportunity Lantern Pharma projects a $15B–$20B aggregate market opportunity and warned funding needs are intensifying on Mar 30, 2026, increasing the probability of near-term financing actions.

Lantern Pharma Flags $15B–$20B Market Opportunity: Lantern Pharma projects a $15B–$20B aggregate market opportunity and warned funding needs are intensifying on Mar 30, 2026, increasing the probability of… 👈 Read full analysis #LanternPharma #MarketOpportunity #Biotech #Funding #Pharmaceuticals